The chronic inflammation associated with IBD causes continuous damage and repair of the intestinal lining, leading to genetic mutations and cellular abnormalities. Additionally, the presence of inflammatory mediators like cytokines and free radicals can contribute to the development of carcinogenesis. Immunosuppressive therapies used to treat IBD may also play a role in altering cancer risk.
